TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Stroke prevention devices for TAVR fail to make an impact

Cerebral embolic protection devices are "compelling," researchers wrote, but current data does not suggest they make a significant impact on patient outcomes.

cardiologists evaluating the human heart to provide a treatment strategy

Redo TAVR: Supra-annular, intra-annular valves linked to comparable outcomes

When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival. 

womanconsultation.jpg

Women live longer after TAVR than men

Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.

heart data research doctor cardiologist AI

Popular weight loss drug linked to key benefits for patients undergoing TAVR, PCI

Two separate studies explored the value of treating heart patients with tirzepatide. 

Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban

When it came to all-cause mortality and ischemic stroke, however, the two popular DOACs were associated with comparable outcomes. 

The SoloPace Fusion Temporary Pacing System from Solo Pace Inc. is deigned to eliminate the need for right ventricular (RV) lead placement, which requires the added procedural step to gaining venous access. This can cut procedure time and mitigate possible complication risks. For interventional cardiologists using improvised left ventricular (LV) pacing, this system can replace ad-hoc clip assemblies, subcutaneous needles and exposed wire connections, which are known sources of inconsistent pace capture.

New temporary pacing system for TAVR launches in US

New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.

robot reviewing heart data

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

Displaying 1 - 8 of 597
Design by Adaptive Theme